Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BRENTUXIMAB VEDOTIN Cause Neoplasm progression? 116 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 116 reports of Neoplasm progression have been filed in association with BRENTUXIMAB VEDOTIN (ADCETRIS). This represents 1.2% of all adverse event reports for BRENTUXIMAB VEDOTIN.

116
Reports of Neoplasm progression with BRENTUXIMAB VEDOTIN
1.2%
of all BRENTUXIMAB VEDOTIN reports
43
Deaths
40
Hospitalizations

How Dangerous Is Neoplasm progression From BRENTUXIMAB VEDOTIN?

Of the 116 reports, 43 (37.1%) resulted in death, 40 (34.5%) required hospitalization, and 4 (3.4%) were considered life-threatening.

Is Neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BRENTUXIMAB VEDOTIN. However, 116 reports have been filed with the FAERS database.

What Other Side Effects Does BRENTUXIMAB VEDOTIN Cause?

Off label use (1,370) Neuropathy peripheral (695) Pyrexia (693) Febrile neutropenia (684) Death (602) Neutropenia (561) Hodgkin's disease (512) Nausea (392) Diarrhoea (385) Anaemia (374)

What Other Drugs Cause Neoplasm progression?

PALBOCICLIB (10,885) SUNITINIB MALATE (1,920) CYCLOPHOSPHAMIDE (1,588) CARBOPLATIN (1,370) AXITINIB (1,315) DOXORUBICIN (1,276) LETROZOLE (1,225) PACLITAXEL (1,180) CRIZOTINIB (1,161) VINCRISTINE (1,106)

Which BRENTUXIMAB VEDOTIN Alternatives Have Lower Neoplasm progression Risk?

BRENTUXIMAB VEDOTIN vs BREO ELLIPTA BRENTUXIMAB VEDOTIN vs BREXANOLONE BRENTUXIMAB VEDOTIN vs BREXPIPRAZOLE BRENTUXIMAB VEDOTIN vs BREXUCABTAGENE AUTOLEUCEL BRENTUXIMAB VEDOTIN vs BRIGATINIB

Related Pages

BRENTUXIMAB VEDOTIN Full Profile All Neoplasm progression Reports All Drugs Causing Neoplasm progression BRENTUXIMAB VEDOTIN Demographics